Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06119204
Other study ID # SAFE-LCD study (IRAS:321277)
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 26, 2024
Est. completion date October 2026

Study information

Verified date March 2024
Source Oviva UK Ltd
Contact Felix Shirmann, Dr
Phone +44 0207 622 4777
Email felix.schirmann@oviva.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

SAFE-LCD study is a randomised controlled trial aiming to develop and evaluate a safe, cost-effective, easily accessible, digital Low-Calorie Diet (LCD) programme for insulin-treated adults with Type 2 diabetes (T2D), a world-first innovation. The study plans to enrol 72 participants who will be randomly allocated to either receive the intervention or will be provided with weight loss advice suitable for insulin-treated patients through accessing the NHS 12-week weight loss plan. The intervention arm will follow Oviva Diabetes Remission Insulin (ODR-I) programme which includes expert dietitian coaching, support of a Diabetes Nurse, the Oviva app (with a 12-month weight prediction chart), a Capilar Blood Glucose (CBG) meters (for enhanced safety in view of concerns re hypo- and hyper-glycaemia), and BodyTrace weight scales. If successful, this project will provide game-changing evidence for the support of insulin-treated T2D patients and for NHS commissioning of the digital Low-Calorie programme driving patient benefits and cost-savings.


Description:

Insulin treatment in Type 2 diabetes (T2D) patients is linked to poorer quality of life and and increased risk of complications due to disease progression. This research study will be a randomised control trial (RCT) which is the highest quality form of medical evidence. It aims to develop and evaluate a safe, efficacious, cost-effective, easily accessible, digital Low-Calorie Diet (LCD) programme for insulin-treated adults with Type 2 diabetes (T2D), a world-first innovation. The study plans to enrol 72 participants who will be randomly allocated to either receive the intervention or will be provided with weight loss advice through accessing the NHS 12-week weight loss plan. The intervention will involve a 12-week Total Diet Replacement (TDR) diet of approximately 850 calories per day through four TDR products daily, followed by a 6-week food reintroduction period and weight maintenance support for 8 months. Care will be delivered fully remotely by Oviva's Diabetes Specialist Dietitians and Diabetes Specialist Nurse. Treatment aims are to achieve weight loss, improve diabetes control quality of life and decrease or in some cases discontinue insulin treatment. The evaluation of ODR-I with independent clinical and health-economic evaluations will be undertaken by University College London and Insight Health Improvement and will be published in respected academic journals. This groundbreaking research has the potential to achieve significant reductions in insulin use and to transform the lives of tens of thousands of people living with Type 2 diabetes. It will also save the NHS millions- if it is rolled out to just 62,000 patients a year, it will save more than £229 million a year in Type 2 Diabetes management costs across medications, monitoring, and hospital and General Practitioner(GP) usage.


Recruitment information / eligibility

Status Recruiting
Enrollment 72
Est. completion date October 2026
Est. primary completion date September 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Registered with a GP practice within the confirmed NHS site - Humber and North Yorkshire - Diagnosis of type 2 diabetes treated with insulin - Age 18-70 years inclusive - BMI =30kg/m² (adjusted to =27 kg/m² in ethnic minority groups) - Upper body weight limit of 180kg (if using BodyTrace scales) - Ability to speak, read and receive care in English language - Access to the internet and a personal email address - Access to and ability to use a smartphone - Willing to test blood glucose up to 7 times a day (for up to 4 months) to ensure clinical safety. - Participants capable to provide written informed consent and willing to comply with the trial protocol Exclusion Criteria: - C-peptide <200 pmol/L AND positive Glutamic Acid Decarboxylase(GAD) antibodies assessing for misdiagnosed Type 1 diabetes and risk of diabetic ketoacidosis. - Type 1 diabetes mellitus, Mitochondrial diabetes, Maturity-Onset Diabetes of the Young (MODY) diabetes or diagnostic uncertainty (e.g. dual codes on patient record) Type 2 diabetes with history of diabetic ketoacidosis (DKA) or ketosis prone - Clinically assessed hypoglycemia unawareness (via GOLD score (11, 12)) - Concomitant medication use clinically deemed to affect metabolic rate and body weight - A major cardiovascular event within 6 months - Severe angina, uncontrolled arrhythmia or known prolonged QT syndrome - Warfarin or Rivaroxoban therapy - Estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73m² - A condition precipitating fluid overload (e.g. New York Heart Association class III-IV congestive heart failure) - Active liver disease (except non-alcoholic fatty liver disease (NAFLD) - Active gallstone disease or known presence of gallstones - Active cancer, receiving cancer treatment or received cancer treatment within past 24 months - Known proliferative retinopathy that has not been treated - Uncontrolled epilepsy - Uncontrolled thyroid dysfunction - Active or suspected peptic ulcer disease - Gout - History of bariatric surgery (previous band/balloon allowed if removed<12 months) - Clinically diagnosed with an active eating disorder - Clinically significant diagnosed/self-reported psychiatric disease that may interfere with study compliance - Known or suspected alcohol or recreational drug misuse - Milk allergy (Nualtra, TDR allergens) - Soya allergy (Nualtra, TDR allergens) - Vegan (Nualtra, animal derived Vit D) - Pregnancy or planning pregnancy within study period - Lactating - Currently on a weight management programme or had in last 3 months or had over 5% weight loss in previous 6 months - Current participation in other clinical intervention trials

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Oviva programme
Total diet replacement for insulin-treated patients
Usual care
NHS 12 week weight loss programme

Locations

Country Name City State
United Kingdom Hull University Teaching Hospital NHS Trust Hull

Sponsors (3)

Lead Sponsor Collaborator
Oviva UK Ltd Hull University Teaching Hospitals NHS Trust, University College, London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Weight loss absolute: kg weight loss at 12 months
Secondary The number of participants reducing or ceasing insulin at month 3, 6, 12 and 24
Secondary The number of participants reducing or ceasing other diabetes medications at month 3, 6, 12 and 24
Secondary The number of participants reducing or ceasing cholesterol medications at month 3, 6, 12 and 24
Secondary The number of participants reducing or ceasing blood pressure medications at month 3, 6, 12 and 24
Secondary Hba1c (mmol/l) changes at month 3, 6, 12 and 24
Secondary Diabetes remission rate HbA1c below 6.5% (48 mmol/mol) and cessation of all diabetes medication for at least 3 months at months 3, 6, 12 and 24
Secondary Fasting and 2 hour postprandial/random glucose (mmol/L) (measured via CBG meters) 1 year, throughout the study
Secondary Weight loss relative: %, incl. the proportion of people achieving >5%, >10%, >15%, and >20% body weight loss at 3, 6 and 24 months
Secondary Cardiovascular disease risk score (QRisk) Low Risk: A risk score of less than 10% means that there is less than a one in ten chance of developing cardiovascular disease in the next 10 years. Moderate Risk: A risk score of 10-20% means that there is between a one to two in ten chance of developing cardiovascular disease in the next 10 years. High Risk : A risk score of 20% equates to at least a two in ten chance of developing cardiovascular disease in the next 10 years. at months 12 and 24
Secondary Diabetes-related emotional distress (DDS17) The scale is used to measure emotional distress related to diabetes. It yields 4 sub-scales (Emotional burden, Regimen-related distress, Physician-related distress and Interpersonal distress). An overall distress score based on the average responses on the 1-6 scale (1"not a problem" to 6 "a very significant problem'') for all 17 items.
A mean question score of 3 or higher (moderate distress) as a level of distress worthy of clinical attention.
at month 6, 12 and 24
Secondary Diabetes Stigma Assessment Scale Type 2 (DSAS-2) DSAS-2 is a valid and reliable self-report measure of diabetes-related stigma. It consists of three subscales: Treated Differently, Blame and Judgment, and Self-stigma. The score can be calculated for each subscale and in total. The higher the score the bigger the stigma. at months 6, 12, and 24
Secondary EuroQol 5 Dimension 5 Level (EQ-5D) EQ5D is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Higher scores indicate more severe or frequent problems. at month 6, 12 and 24
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04420936 - Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program N/A
Completed NCT04025099 - Internal Cues Versus External Cues for Eating and Activity N/A
Completed NCT04766528 - Effect of Diet on the Microbiota / Endoccanabinoidome Axis in Response to Physical Activity N/A
Completed NCT03277040 - Diet, Eating, and Lifestyle Improvement for Valued Employees and Their Relatives N/A
Active, not recruiting NCT05544461 - Piloting a Web-based Personalised Nutrition App (eNutri) With UK University Students N/A
Active, not recruiting NCT04748835 - The SEEA (SCI Energy Expenditure and Activity) Study
Active, not recruiting NCT04991142 - Models of Nutrition From Continuous Glucose Monitors
Recruiting NCT04487015 - A Digital Approach to Improving Carbohydrate Periodisation Behaviours in Athlete: SMART+ Study N/A
Completed NCT03748056 - Targeted Food Incentives to Improve Diet Quality and Health Among Adults N/A
Not yet recruiting NCT05960396 - Exploring the Mechanism of Dietary Pattern Improving MAFLD N/A
Enrolling by invitation NCT04314882 - The Danish National Survey of Diet and Physical Activity 2021-2023
Terminated NCT04677322 - TO ASSESS THE EFFECTIVENESS OF THE INTERVENTION OF THE LOW-SODIUM DIET IN PATIENTS WITH HTA
Completed NCT03855098 - Biomarkers of Food Intake Using a Cross-over Feeding Study N/A
Completed NCT03124446 - Mindfulness-Based College: Stage 1 N/A
Completed NCT03993652 - Kids FIRST: Family-based Intervention to Reduce Snacking and Screen Time in Children N/A
Completed NCT04766034 - Impact of Behavioral Economic Strategies on Low-Income Older Adults' Food Choices in Online Retail Settings N/A
Completed NCT03698123 - Performance Nutrition for Residents and Fellows N/A
Completed NCT03913871 - Text Message Program to Improve Eating Behaviors Among African Americans in New Orleans N/A
Completed NCT03941392 - Nutritional Study in Spanish Pediatric Population
Completed NCT03400566 - Effects of Experiential Learning on Vegetable Intake in Preschool Children N/A